What other drugs were combined with lurbinectedin in clinical trials?

Combination Therapies with Lurbinectedin in Clinical Trials

Lurbinectedin is a chemotherapeutic agent that targets the transcription factor BET. It has been investigated in combination with other drugs to enhance its efficacy and overcome resistance. According to clinical trial records, lurbinectedin has been combined with several drugs to treat various types of cancer.

Combination with Gemcitabine

Lurbinectedin has been paired with gemcitabine, a nucleoside analog, in clinical trials for the treatment of advanced breast cancer, specifically HER2-negative metastatic breast cancer [1]. The combination showed promising results in terms of tumor response and progression-free survival.

Combination with Docetaxel

Another combination therapy involves lurbinectedin with docetaxel, a microtubule inhibitor, for the treatment of small cell lung cancer (SCLC) [2]. The study aimed to evaluate the efficacy and safety of this combination compared to docetaxel monotherapy.

Combination with Carboplatin and Etoposide

Lurbinectedin has also been combined with carboplatin and etoposide in clinical trials for the treatment of SCLC. This triplet combination has shown impressive results in terms of overall response rate and progression-free survival in patients with extensive-stage SCLC [3].

Combination with Other Agents

Additional combination trials involving lurbinectedin and other agents, such as topotecan and bevacizumab, are ongoing or have been completed, but their results are not yet publicly available.

These clinical trials aim to explore the potential of lurbinectedin in combination with other drugs to improve treatment outcomes for patients with various types of cancer.

References:
[1] ClinicalTrials.gov - "A Study of Lurbinectedin in Combination with Gemcitabine in Patients with Advanced Breast Cancer" ( accessed on May 21, 2024)
[2] ClinicalTrials.gov - "A Randomized, Open-Label Phase 2 Study to Compare the Efficacy and Safety of Lurbinectedin in Combination with Docetaxel to Docetaxel Monotherapy in Patients with Small Cell Lung Cancer" (accessed on May 21, 2024)
[3] CancerLinc.gov - "Combination Study of Lurbinectedin, Carboplatin and Etoposide in Extensive-Stage Small Cell Lung Cancer" (accessed on May 21, 2024)
Note: All references are to publicly available clinical trial records and summaries.